Report: Penetrating crowded heart failure market could prove difficult for Omecamtiv Mecarbil

Cytokinetics ’ new heart failure drug, Omecamtiv Mecarbil (OM), will have to target patient subgroups in order to succeed in the crowded heart failure market, says GlobalData in its recent report.

Source: Drug Development Technology - October 20, 2016 Category: Pharmaceuticals Source Type: news